<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949335</url>
  </required_header>
  <id_info>
    <org_study_id>SUR-CAT-652-2001</org_study_id>
    <nct_id>NCT03949335</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, multicenter, bilateral, comparative, three-way masked&#xD;
      (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15&#xD;
      sites. Up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted&#xD;
      subjects, resulting in approximately 244 evaluable subjects (122 per lens group) at 6 months.&#xD;
      After informed consent is obtained and confirmation that all eligibility criteria are met,&#xD;
      the eye(s) may be treated according to randomization.&#xD;
&#xD;
      After signing the informed consent form, subjects meeting all eligibility criteria will be&#xD;
      randomized in a masked fashion to a treatment group: either the investigational IOL Model&#xD;
      ZFR00V or the control IOL Model ZCB00. Prior to randomization, the investigator will choose&#xD;
      which eye to operate on first for each subject at his/her discretion based on his/her&#xD;
      standard clinical practice (e.g., the eye with the worse cataract, poorer best corrected&#xD;
      distance vision and/or more severe optical/visual complaints). All subjects are intended to&#xD;
      have bilateral cataract surgery with the second eye surgery occurring after the 1-week&#xD;
      postoperative exam for the first eye, but no more than 30 days after the first eye surgery.&#xD;
      All subjects will be examined through 6 months postoperatively according to the visit&#xD;
      schedule&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Only the surgeon and the operative staff will know which lens type is implanted and will be unmasked throughout the study. There may also be site coordinators and other site study staff, such as those performing slit-lamp exams, who will be unmasked. Unmasked study staff and study subjects will be instructed not to disclose the lens type the subject received or to talk about the lens to any subjects or masked evaluators.&#xD;
The subjects and the study technicians performing the postoperative vision tests are to be masked through study completion. To maintain subject/technician-masking through the 6-month study exams, a masking plan will be tailored for each site to detail how lens assignment information will be concealed from masked technicians.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm</measure>
    <time_frame>6 months (postoperative)</time_frame>
    <description>mean photopic monocular Distance Corrected Near Visual Acuity results at 40 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monocular Distance-Corrected Intermediate Visual Acuity at 66 cm</measure>
    <time_frame>6 months (postoperative)</time_frame>
    <description>mean photopic monocular Distance-Corrected Intermediate Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular Distance-Corrected Near Visual Acuity at 33 cm</measure>
    <time_frame>6 months postoperative</time_frame>
    <description>mean photopic monocular Distance-Corrected Near Visual Acuity results at 33 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular Photopic Best-Corrected Distance Visual Acuity</measure>
    <time_frame>6 months postoperative</time_frame>
    <description>mean monocular Best-Corrected Distance Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular Distance-Corrected Defocus Curve</measure>
    <time_frame>6 months postoperative</time_frame>
    <description>Mean monocular (first eye) distance-corrected defocus curve for each lens group at 6 months in the safety population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle Wear</measure>
    <time_frame>6 months postoperative</time_frame>
    <description>Spectacle wear is determined via the PRO questionnaire instrument and defined as wearing glasses or contacts &quot;none of the time&quot; in all 4 conditions (distance vision, intermediate vision, near vision and overall vision) at 6 months postoperative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Cataract</condition>
  <condition>Corneal Astigmatism</condition>
  <arm_group>
    <arm_group_label>Investigational</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bilateral implantation with investigational IOL Model ZFR00V</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilateral implantation with control IOL Model ZCB00</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOL Model ZFR00V</intervention_name>
    <description>Bilateral implantation with Investigational IOL Model ZFR00V</description>
    <arm_group_label>Investigational</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOL Model ZCB00</intervention_name>
    <description>Bilateral Implantation with control IOL Model ZCB00</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  be at least 22 years old&#xD;
&#xD;
          -  have cataracts in both eyes&#xD;
&#xD;
          -  sign the written informed consent&#xD;
&#xD;
          -  be willing and able to comply with examination procedures&#xD;
&#xD;
          -  understand, read and write English to complete informed consent and questionnaires&#xD;
&#xD;
          -  be available for study follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently participating in any other clinical study or have participated in a clinical&#xD;
             study during the last 60 days&#xD;
&#xD;
          -  have a certain disease/illness such as poorly-controlled diabetes&#xD;
&#xD;
          -  have certain ocular conditions such as uncontrolled glaucoma&#xD;
&#xD;
          -  Is taking medication that may affect vision&#xD;
&#xD;
          -  Subject is pregnant, plan to become pregnant during the study, or is breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Surgical Vision Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Empire Eye &amp; Laser Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katzen Eye Care &amp; Laser Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Clinic</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Eye Care &amp; Laser Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Blue Ash</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Associates, PC</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina EyeCare Physicians</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkeley Eye Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Eye and Laser Center</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehmann Eye Center</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Focal Point Vision</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarus Eye Centre</name>
      <address>
        <city>Lacey</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>August 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.</ipd_description>
    <ipd_url>http://yoda.yale.edu/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03949335/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03949335/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>272 subjects were bilaterally implanted with either the study or control lens. 135 subjects were bilaterally implanted with the study lens and 137 subjects were bilaterally implanted with the control lens. All 272 subjects were bilaterally implanted with the same IOL model in both eyes.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ZFR00V</title>
          <description>Study Lens</description>
        </group>
        <group group_id="P2">
          <title>ZCB00</title>
          <description>Control Lens</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZFR00V</title>
          <description>Study Lens</description>
        </group>
        <group group_id="B2">
          <title>ZCB00</title>
          <description>Control Lens</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 to 69</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 to 79</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or = 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian (including Indian)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm</title>
        <description>mean photopic monocular Distance Corrected Near Visual Acuity results at 40 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
        <time_frame>6 months (postoperative)</time_frame>
        <population>The safety (SP) population for monocular Distance-Corrected Near Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Distance-Corrected Near Visual Acuity (DCNVA) at 40 cm</title>
          <description>mean photopic monocular Distance Corrected Near Visual Acuity results at 40 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
          <population>The safety (SP) population for monocular Distance-Corrected Near Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.138"/>
                    <measurement group_id="O2" value="0.522" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocular Distance-Corrected Intermediate Visual Acuity at 66 cm</title>
        <description>mean photopic monocular Distance-Corrected Intermediate Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population</description>
        <time_frame>6 months (postoperative)</time_frame>
        <population>The safety (SP) population for monocular Distance-Corrected Intermediate Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Monocular Distance-Corrected Intermediate Visual Acuity at 66 cm</title>
          <description>mean photopic monocular Distance-Corrected Intermediate Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population</description>
          <population>The safety (SP) population for monocular Distance-Corrected Intermediate Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.060" spread="0.115"/>
                    <measurement group_id="O2" value="0.335" spread="0.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocular Distance-Corrected Near Visual Acuity at 33 cm</title>
        <description>mean photopic monocular Distance-Corrected Near Visual Acuity results at 33 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
        <time_frame>6 months postoperative</time_frame>
        <population>The safety (SP) population for monocular Distance-Corrected Near Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Monocular Distance-Corrected Near Visual Acuity at 33 cm</title>
          <description>mean photopic monocular Distance-Corrected Near Visual Acuity results at 33 cm for ZFR00 and control first eyes in the safety population at 6 months</description>
          <population>The safety (SP) population for monocular Distance-Corrected Near Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.151"/>
                    <measurement group_id="O2" value="0.608" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocular Photopic Best-Corrected Distance Visual Acuity</title>
        <description>mean monocular Best-Corrected Distance Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population.</description>
        <time_frame>6 months postoperative</time_frame>
        <population>The safety (SP) population for monocular Best-Corrected Distance Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Monocular Photopic Best-Corrected Distance Visual Acuity</title>
          <description>mean monocular Best-Corrected Distance Visual Acuity results at 6 months for ZFR00 and control first eyes in the safety population.</description>
          <population>The safety (SP) population for monocular Best-Corrected Distance Visual Acuity include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.087"/>
                    <measurement group_id="O2" value="-0.045" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Noninferiority margin equals -0.1</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>-0.010</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Monocular Distance-Corrected Defocus Curve</title>
        <description>Mean monocular (first eye) distance-corrected defocus curve for each lens group at 6 months in the safety population</description>
        <time_frame>6 months postoperative</time_frame>
        <population>The safety (SP) population for monocular Distance-Corrected Defocus Curve include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Monocular Distance-Corrected Defocus Curve</title>
          <description>Mean monocular (first eye) distance-corrected defocus curve for each lens group at 6 months in the safety population</description>
          <population>The safety (SP) population for monocular Distance-Corrected Defocus Curve include all first eyes implanted with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>diopter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-3.6" upper_limit="-3.0"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.1" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spectacle Wear</title>
        <description>Spectacle wear is determined via the PRO questionnaire instrument and defined as wearing glasses or contacts &quot;none of the time&quot; in all 4 conditions (distance vision, intermediate vision, near vision and overall vision) at 6 months postoperative.</description>
        <time_frame>6 months postoperative</time_frame>
        <population>The safety (SP) population for spectacle independence include all subjects implanted bilaterally with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
        <group_list>
          <group group_id="O1">
            <title>ZFR00V</title>
            <description>Study Lens</description>
          </group>
          <group group_id="O2">
            <title>ZCB00</title>
            <description>Control Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Spectacle Wear</title>
          <description>Spectacle wear is determined via the PRO questionnaire instrument and defined as wearing glasses or contacts &quot;none of the time&quot; in all 4 conditions (distance vision, intermediate vision, near vision and overall vision) at 6 months postoperative.</description>
          <population>The safety (SP) population for spectacle independence include all subjects implanted bilaterally with either a test or control IOL with data available at 6 months postoperative (i.e., no data imputation)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A little/Some/Most/All of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Adverse events (AEs) were planned to be reported for each eye separately and AEs not related to eyes were counted and represented in both the eyes.&#xD;
The total number of participants affected by SAE is total number of unique eyes. If an eye has multiple SAEs, the number of affected participant is one (1) but list multiple number of SAEs.&#xD;
Only other (not including serious) adverse events that exceed the frequency threshold of 5% are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>ZFR00V First Eye</title>
          <description>Study Lens</description>
        </group>
        <group group_id="E2">
          <title>ZCB00 First Eye</title>
          <description>Control Lens</description>
        </group>
        <group group_id="E3">
          <title>ZFR00V Second Eye</title>
          <description>Study Lens</description>
        </group>
        <group group_id="E4">
          <title>ZCB00 Second Eye</title>
          <description>Control Lens</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Exacerbation of congestive heart failure and atrial fibrillation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystoid Macular Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Retinal Detachment/tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Macular Hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Herpes Simplex Virus Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Corneal Ulcers</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Due to high blood pressure and high blood sugar</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia requiring surgical repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Due to pneumonia due to influenza</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractured right fibula and dislocated ankle requiring surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Undesirable Optical Phenomena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Toxic Anterior Segment Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypopyon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Retained lens material resulting in secondary surgical intervention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Undesirable Optical Phenomena</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must review results communication prior to public release and can embargo communications regarding trial results at anytime.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenia Thomas, OD</name_or_title>
      <organization>Johnson &amp; Johnson Surgical Vision</organization>
      <phone>+1 657 2903260</phone>
      <email>ethoma39@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

